Noile-Immune Biotech (TSE:4893) Total Debt per Share: 円0.00 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4893 Noile-Immune Biotech Inc TSE:4893
45 GF Score
Price 円139.00
GF Value 円15.43
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Noile-Immune Biotech Total Debt per Share?

Noile-Immune Biotech TSE:4893 -1.42% 45 Total Debt per Share is 円0.00 as of Jun. 2026. GuruFocus rates TSE:4893 with a GF Score™ of 45/100 and a GF Value™ of 円15.43 (Significantly Overvalued). The stock has 3 warning signs investors should review.

円0.00 (As of Jun. 2026)

Total Debt per Share is calculated as total debt divided by Shares Outstanding (EOP). Total debt is calculated as Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. Noile-Immune Biotech's Total Debt Per Share for the quarter that ended in Jun. 2026 was 円0.00.

Noile-Immune Biotech Total Debt per Share Historical Data

* Premium members only.

The historical data trend for Noile-Immune Biotech's Total Debt per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Noile-Immune Biotech Total Debt per Share Chart

Noile-Immune Biotech Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Debt per Share
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Noile-Immune Biotech Quarterly Data
Dec20 Dec21 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Total Debt per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
TSE:4893
45GF Score
Noile-Immune Biotech Inc TSE:4893
Total Debt per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Noile-Immune Biotech Total Debt per Share Calculation

Noile-Immune Biotech's Total Debt Per Share for the fiscal year that ended in Dec. 2025 is calculated as:

Total Debt Per Share=(Long-Term Debt & Capital Lease Obligation+Short-Term Debt & Capital Lease Obligation)/Shares Outstanding (EOP)
=(0.00+0.00)/43.30
=0.00

Noile-Immune Biotech's Total Debt Per Share for the quarter that ended in Jun. 2026 is calculated as:

Total Debt Per Share=(Long-Term Debt & Capital Lease Obligation+Short-Term Debt & Capital Lease Obligation)/Shares Outstanding (EOP)
=(0.00+0.00)/43.40
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Debt per Share →
What does a Total Debt per Share of 円0.00 mean?
Noile-Immune Biotech (TSE:4893) has a Total Debt per Share of 円0.00 as of Jun. 2026. Total debt per share equals the per-share value of a company's long-term and short-term debt. View historical data on Noile-Immune Biotech and its competitors.
Is Noile-Immune Biotech's Total Debt per Share too high?
Noile-Immune Biotech's current Total Debt per Share is 円0.00. Overall, Noile-Immune Biotech has a GF Score™ of 45/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Noile-Immune Biotech's Total Debt per Share compare to VRTX and REGN?
Noile-Immune Biotech's Total Debt per Share of 円0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Debt per Share for a Biotechnology company?
A good Total Debt per Share depends on the Biotechnology industry context. However, Total Debt per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Debt per Share mean?
A high Total Debt per Share can signal that a stock is expensive relative to its fundamentals. Total debt per share equals the per-share value of a company's long-term and short-term debt. View historical data on Noile-Immune Biotech and its competitors. Noile-Immune Biotech's current Total Debt per Share is 円0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Noile-Immune Biotech stock overvalued right now?
Based on GuruFocus' analysis, Noile-Immune Biotech (TSE:4893) is currently considered Significantly Overvalued. The stock's GF Value™ is 円15.43, compared to a current price of 円139.00 — trading 800.8% above its estimated fair value. The current Total Debt per Share is 円0.00. Noile-Immune Biotech's overall GF Score™ is 45/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Debt per Share calculated?
Total Debt per Share is calculated from a company's financial statements. For Noile-Immune Biotech (TSE:4893), the current Total Debt per Share is 円0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Noile-Immune Biotech (TSE:4893) Overvalued in 2026?

Based on GuruFocus' analysis, Noile-Immune Biotech stock appears to be overvalued. The current stock price of 円139.00 is trading 800.8% above its estimated GF Value™ of 円15.43. GuruFocus considers Noile-Immune Biotech to be Significantly Overvalued.

Key valuation signals for TSE:4893:

  • Total Debt per Share: 円0.00
  • GF Value™: 円15.43 vs. price of 円139.00 (800.8% above fair value)
  • GF Score™: 45/100 with 3 warning signs

No single metric tells the full story. See the TSE:4893 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Noile-Immune Biotech Business Description

Address 2-12-10 Shiba-Daimon, 5th Floor, T&G Hamamatsucho Building, Minato-ku, Yamaguchi, Tokyo, JPN, 105-0012
Noile-Immune Biotech Inc is engaged in the development of CAR-T cell therapy for solid cancers using its proprietary technology. The company's development pipeline and collaborative projects with other companies include different product candidates such as NIB102, NIB103, NIB104, ADAP01, AUTL01, etc. It operates in a single segment, the cancer immunotherapy drug discovery business.
45GF Score

Get the complete analysis for TSE:4893

Total Debt per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円139.00
Price
円15.43
GF Value